Cambridge-based AVEO Pharmaceuticals Inc. (Nasdaq: AVEO) said it has started enrolling patients in a Phase 2 exploratory biological marker study of tivozanib, its lead treatment for renal cell carcinoma (RCC).

A primary goal is to evaluate biomarkers in blood and archived tissue samples and their correlation with tivozanib’s clinical activity and/or drug-related toxicity, according to the company. A biomarker can help tell how well the body responds to a treatment.

SOURCE